Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia

Acta Pharmacologica Sinica

Volumn 23, Issue 11, 2002, Pages 1040-1044

  Cai, Wei Min ^a   Xu, Jun ^a   Chen, Bing ^a   Zhang, Fu Min ^b   Huang, Yuan Zhu ^b   Zhang, Yin Di ^c  

^a JINLING HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cytochrome P 450 CYP2D6; Genotype; Pharmacodynamics; Propafenone; Ventricular dysfunction

Indexed keywords

CYTOCHROME P450 2D6; PROPAFENONE; ANTIARRHYTHMIC AGENT;

ADULT; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART VENTRICLE EXTRASYSTOLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; AGED; BLOOD; GENETICS; HEART ARRHYTHMIA; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROPAFENONE; VENTRICULAR PREMATURE COMPLEXES;

EID: 0036844558     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hii JT, Duff HJ, Burgess ED. Clinical Pharmacokinetics of propafenone. Clin Pharmacokinet 1991; 21: 1-10.
2. Volz M, Mitrovic V, Schlepper M. Steady-state plasma concentrations of propafenone-chirality and metabolism. Int J Clin Pharmacol Ther 1994; 32: 370-5.
3. Cai WM, Chen B, Cai MH, Zhang YD. CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects. Acta Pharmacol Sin 1999; 20: 720-4.
4. Cai WM, Zhang YD, Chen B, Cai MH, Luo JP, Ling SS. Simultaneous modeling pharmacokinetics and pharmacodynamics of propafenone in healthy Chinese. Acta Pharmacol Sin 2001; 22: 956-60.
5. Labbe L, O'Hara G, Lefebvre M, Lessard E, Gilbert M, Adedoyin A, et al. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Clin Pharmcol Ther 2000; 67: 44-57.
6. Cai WM, Chen B, Tao X, Ling SS, Zhang YD. Correlation of genetic polymorphism of cytochrome P4502D6 with dextromethorphan oxidative metabolism in Chinese. Chin J Med Genet 2000; 17: 181-4.
7. Chen B, Cai WM, Wan W. Determination of propafenone eanatiomeric concentrations in human plasma by stereoselective high performance liquid chromatography. Chin Pharm J 1998; 33: 546-9.
8. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin [Published erratum appears in Clin Pharmacol Ther 1994; 55: 648]. Clin Pharmacol Ther 1992; 51: 388-97.
9. Horai Y, Nakamo M, Ishizaki T, Ishikawa K, Zhou HH, Shou BJ, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207.
10. Sohn DR, Shim SG, Park CW, Kusaka M, Chiba K, Ishizaki T. Metoprolol oxidation polymorphism in a Korean population: Comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991; 32: 504-7.
11. Huang JD, Chuang SK, Cheng CL, Lai ML. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin Pharmacol Ther 1999; 65: 402-7.
12. Mihara K, Suzuki A, Kondo T, Yasui N, Furukori H, Nagshima U, et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther 1999; 65: 291-4.
13. Yoon YR, Cha IJ, Shon JH, Kim KA, Cha YN, Jang IJ, et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther 2000; 67: 567-76.